Drug Profile

Research programme: hypersensitivity therapies - RemAb Theraepeutics

Alternative Names: DP1000-RA0118; DP600-RA0118; RA-0118

Latest Information Update: 03 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator RemAb Therapeutics
Class Antiallergics; Immunotherapies; Polymers
Mechanism of Action Antibody modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Hypersensitivity

Most Recent Events

30 Sep 2025 Preclinical trials in Hypersensitivity in Spain (Parenteral) (RemAb Therapeutics pipeline, September 2025)
31 Mar 2022 Pharmacodynamics data from a preclinical studies in Hypersensitivity released by RemAb Therapeutics
08 Sep 2021 RemAb Therapeutics has patents pending for hypersensitivity therapies in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com